Physician profile
Sumit Bhatia
NPI 1780670596
$1,487.79
in general payments reported to CMS, 2019-2025
12 companies · $297 in 2025
The $297 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $101 · 2021: $57.36 · 2022: $266 · 2023: $251 · 2024: $214 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $729 · Entertainment: $33.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.87 |
| Entertainment | $33.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $270.51 | 2023-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $221.76 | 2020-2024 | Eylea Hd, Eylea |
| Abbvie INC. | $188.56 | 2022-2025 | Ozurdex |
| Allergan, INC. | $177.99 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $147.53 | 2019 | |
| Genentech USA, INC. | $127.12 | 2022-2025 | Vabysmo |
| Harrow Eye, LLC | $125.00 | 2025 | Iheezo, Triesence |
| Alcon Vision LLC | $66.31 | 2019 | |
| Astellas Pharma US INC | $57.21 | 2024-2025 | Izervay |
| Alimera Sciences, INC. | $56.44 | 2023-2024 | Iluvien, Yutiq |
| Optos, INC. | $33.37 | 2023-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Vyera Pharmaceuticals, LLC | $15.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Bhatia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.